missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Mouse VEGFR2/KDR/Flk-1 Biotinylated Antibody, R&D Systems™
Goat Polyclonal Antibody has been used in 2 publications
Brand: R&D Systems BAF644
This item is not returnable.
View return policy
Description
VEGFR2/KDR/Flk-1 Polyclonal specifically detects VEGFR2/KDR/Flk-1 in Mouse samples. It is validated for Western Blot, Flow Cytometry, ELISA Detection (Matched Antibody Pair).
Specifications
| VEGFR2/KDR/Flk-1 | |
| Polyclonal | |
| Biotin | |
| P35918 | |
| KDR | |
| Mouse myeloma cell line NS0-derived recombinant mouse VEGFR2/KDR/Flk-1, Ala20-Glu762, Accession # P35918 | |
| 50 μg | |
| Primary | |
| Detects mouse VEGFR2/KDR/Flk-1 in ELISAs and Western blots. In sandwich ELISAs, less than 0.5% cross-reactivity with recombinant human VEGFR2, recombinant mouse (rm) VEGF164, rmVEGFR1, rmVEGFR3, rmVEGF-B, and rmVEGF-D is observed. | |
| Mouse | |
| IgG |
| Western Blot, Flow Cytometry, ELISA | |
| LYOPH | |
| Western Blot 0.1 ug/mL, Flow Cytometry 2.5 ug/10^6 cells, ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL | |
| CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), KRD1, Ly73, Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGF R2, VEGFR, VEGFR2, VEGFR-2 | |
| Goat | |
| Affinity Purified | |
| RUO | |
| 3791 | |
| Reconstitute at 0.2 mg/mL in sterile PBS. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction